Vice Provost for Faculty Diversity and Faculty Development
Department / Division
Medicine / Medicine-Rheumatology and Immunology
Durham, NC 27710
Systemic vasculitis, Wegener's granulomatosis, temporal arteritis, Takayasu arteritis, systemic lupus erythematosus, erosive osteoarthritis, antiphospholipid antibody syndrome, women with rheumatic disease, Behcet's syndrome, retroperitoneal fibrosis
My clinical research interests include systemic vasculitis (Wegener's granulomatosis, microscopic polyangiitis, giant cell arteritis, Takayasu arteritis) and multi-disciplinary efforts in the areas of systemic lupus erythematosus and anti-phospholipid syndrome. Dr. E. William St. Clair and I represented Duke in both the RAVE trial, a multi-center, double-blind, controlled trial comparing rituximab with cyclophosphamide in patients with ANCA-associated vasculitis and previously the Wegener's granulomatosis etanercept trial (WGET), a multi-center effort to assess the addition of etanercept to traditional therapy in limited and severe forms of this type of vasculitis.
My area of clinical expertise is in the care of patients with all types of vasculitis, particularly Granulomatosis with Polyangiitis (formerly called Wegener's granulomatosis), Micropscopic Polyangiitis, other ANCA-associated vasculitides, giant cell arteritis, and Takayasu's arteritis. I also care for patients with systemic lupus erythematosus, anti-phospholipid syndrome, and women's health-related rheumatologic diseases. In addition I see all patients and educate trainees about all types of rheumatologic and arthritis conditions. Key words: vasculitis, systemic vasculitis, Wegener's granulomatosis, giant cell (temporal) arteritis, Takayasu arteritis, anti-phospholipid antibody syndrome.
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
Stone, JH; Merkel, PA; Spiera, R; Seo, P; Langford, CA; Hoffman, GS; Kallenberg, CG; St Clair, EW; Turkiewicz, A; Tchao, NK; Webber, L; Ding, L; Sejismundo, LP; Mieras, K; Weitzenkamp, D; Ikle, D; Seyfert-Margolis, V; Mueller, M; Brunetta, P; Allen, NB; Fervenza, FC; Geetha, D; Keogh, KA; Kissin, EY; Monach, PA; Peikert, T; Stegeman, C; Ytterberg, SR; Specks, U; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. New England Journal of Medicine. 2010;363:221-232. (2010) Abstract
Wung, PK; Holbrook, JT; Hoffman, GS; Tibbs, AK; Specks, U; Min, YI; Merkel, PA; Spiera, R; Davis, JC; St Clair, EW; McCune, J; Ytterberg, SR; Allen, NB; Stone, JH; WGET Research Group. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. American Journal of Medicine. 2005;118:1416. (2005) Abstract
Hansen, KE; Moore, KD; Ortel, TL; Allen, NB. Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa. Arthritis and Rheumatism. 1999;42:2250-2252. (1999) Abstract